Rifampicine vermindert de ontstekingsreactie bij patienten met een (matig) ernstige longontsteking.
Completed
- Conditions
- Community Acquired PneumoniaRifampicinLipoteichoid AcidPneumolysininflammatory responsclinical outcome prognosispneumoniaEmergency medicinehospitalSpoedeisende hulpziekenhuisThuis opgelopen longontstekingCURB-65 scorerifampicinelipoteichoidzuurpneumolysineinflammatoire responsprognoseklinische uitkomstpneumonie
- Registration Number
- NL-OMON22991
- Lead Sponsor
- Prof. dr. J.T. van DisselLUMC
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Patient aged 18 years or above;
2. Hospitalization for community acquired pneumonia with CURB65 score ≥ 2.
Exclusion Criteria
1. Known allergy to rifampicin or other rifamycins;
2. Haemolytic anaemia or thrombopenia as side effect of rifampicin in medical history;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does rifampicin modulate the inflammatory response in community-acquired pneumonia via Pneumolysin and Lipoteichoid Acid pathways?
What is the comparative effectiveness of rifampicin versus standard-of-care antibiotics in reducing inflammation in moderate-to-severe pneumonia?
Which biomarkers (e.g., IL-6, CRP) predict response to rifampicin in pneumonia patients with CURB-65 scores and elevated inflammatory markers?
What are the adverse event profiles and management strategies for rifampicin in pneumonia treatment according to LUMC's NL-OMON22991 trial?
How does rifampicin's anti-inflammatory mechanism compare to adjunct therapies like corticosteroids or anti-cytokine agents in pneumonia management?